Related Experiment Videos

The effect of donepezil treatment on cardiovascular mortality

K Sato1, R Urbano, C Yu

  • 1Department of Medicine, Division of Clinical Pharmacology, Autonomic Dysfunction Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

Clinical Pharmacology and Therapeutics
|July 29, 2010
PubMed

Insights

Donepezil hydrochloride, an acetylcholinesterase inhibitor, may reduce cardiovascular mortality in dementia patients. Further clinical trials are needed to confirm this potential survival benefit in Alzheimer's disease and vascular dementia populations.

Area of Science:

  • Pharmacology
  • Cardiology
  • Neurology

Background:

  • Acetylcholine plays a crucial role in cardiac function.
  • Donepezil hydrochloride is an acetylcholinesterase inhibitor used to treat dementia.
  • The cardiovascular effects of donepezil are not fully understood.

Purpose of the Study:

  • To investigate the association between donepezil hydrochloride usage and cardiovascular mortality.
  • To assess the impact of donepezil on overall and cardiovascular mortality in a retrospective cohort.

Main Methods:

  • Retrospective cohort study design.
  • Analysis of mortality data in patients treated with donepezil hydrochloride.
  • Calculation of hazard ratios for total and cardiovascular mortality.

Main Results:

  • Donepezil users showed a reduced hazard ratio for total mortality (0.68, P=0.045).
  • Donepezil users exhibited a significantly lower hazard ratio for cardiovascular mortality (0.54, P=0.042).
  • Confidence intervals for both outcomes suggest a potential survival benefit.

Conclusions:

  • Donepezil hydrochloride may be associated with a survival benefit in patients with dementia.
  • The observed survival benefit should be interpreted cautiously.
  • Prospective clinical trials are necessary to validate these findings and establish causality.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiac Output II: Effect of Stroke Volume on Cardiac Output01:22

Cardiac Output II: Effect of Stroke Volume on Cardiac Output

Cardiac output (CO), the amount of blood the heart pumps per minute, is a parameter in cardiovascular physiology determined by stroke volume and heart rate. Stroke volume, the amount of blood pushed from one of the ventricles per heartbeat, is influenced by preload, afterload, and contractility.
Preload
Preload refers to the initial elongation of the cardiac myocytes before contraction and is related to the volume of blood filling the heart at the end of diastole, or end-diastolic volume. The...
Time Course of Drug Effect01:14

Time Course of Drug Effect

The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50 percent of...